The current Canadian best practice recommendations for stroke care [9] advocate the use of ACE inhibitors as first-line therapy and recommend target systolic BPs of < 140 mm Hg in patients after the acute phase of stroke or TIA, or < 130 mm Hg in those with concomitant diabetes or chronic kidney disease. The gene discussed is ACE; the disease is stroke disorder.